M. Jansen

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

W. Kreuz, Carmen Escuriola Ettingshausen, Vladimír Vdovin et al. · Haemophilia · 2015 · 57 citations · Full text

Life Sciences, Hematology, Immunology +11

Novel, human cell line‐derived recombinant factor <scp>VIII</scp> (Human‐cl rh<scp>FVIII</scp>, Nuwiq^®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics

Anna Klukowska, Tomasz Szczepański, Vladimír Vdovin et al. · Haemophilia · 2015 · 44 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Immunogenicity, efficacy and safety of Nuwiq^® (human‐cl rh<scp>FVIII</scp>) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

Ri Liesner, Marina Abashidze, Olga Aleinikova et al. · Haemophilia · 2017 · 27 citations · Full text

Life Sciences, Immunology, Clinical Immunology +7

Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study

Anna Klukowska, V. Komrska, M. Jansen · Haemophilia · 2010 · 20 citations

Medicine, Hematology, Pharmacology +17

Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery information

Ulrike Nowak‐Göttl, Anne Krümpel, Alexandra Russo et al. · Haemophilia · 2013 · 16 citations

Medicine, Hematology, Pediatrics +14